Prévisions

L'objectif de cours moyen des analystes est de 71,25 € (+43,94 %). La médiane est de 59,24 € (+19,68 %).

Acheter
  7
Conserver
  2
Vendre
  1

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Liquidia ends patent dispute with United Therapeutics and secures market access for Yutrepia

    Liquidia has entered into a global settlement agreement with United Therapeutics, thereby ending all patent litigation. Supply of PAH patients with the dry‑powder formulation Yutrepia remains fully uninterrupted. Liquidia will not appeal and has removed the PH-ILD indication from the product information. » Plus sur finanzen.net


  • Liquidia reports strong YUTREPIA growth, pipeline expansion and positive profitability

    Liquidia said at the Wells Fargo Healthcare Conference that YUTREPIA generated $170 million in revenue in Q2 2026 and that quarterly sales have increased by about $40 million in each of the past three quarters. About 75% of prescriptions are for treatment‑naive patients, and the company reported EBITDA of roughly $100 million, net income of about $80 million and an additional $60 million of cash flow in the quarter. Liquidia is expanding its commercial and clinical programs with 8–10 planned studies in the next 12 months, plans L606 as a follow‑on program, expects long‑term revenue above $1 billion, but faces an outstanding patent ruling. » Plus sur de.investing.com


  • Liquidia Corporation: Yutrepia launch outpaces expectations, litigation likely to be resolved

    The Summers Value Fund named Liquidia Corporation a top contributor after the Yutrepia launch continued to exceed investor expectations and is expected to sustain momentum. The fund expects a near-term favorable resolution of litigation that could unlock further gains. Liquidia shares are up 141.61% over the past year (down 22.08% in the past month) and the company has a market capitalization of $6.24 billion. » Plus sur finance.yahoo.com


  • Greenhaven Road Capital posts Q2 gain, trims concentration and realized short-term gain on Liquidia

    Greenhaven Road Capital reported an approximate 11% net return in Q2 2026 and said it will lower portfolio concentration, increase positions with near-term catalysts and take a more proactive approach to profit-taking. The firm emphasized continued focus on high-quality businesses and research that challenges consensus as several large holdings face near-term events. Greenhaven noted it sold a portion of its Liquidia position after a >30% pre-verdict rise, realizing a short-term gain, and will reassess the investment following the patent dispute outcome. » Plus sur finance.yahoo.com


  • Liquidia Technologies rises premarket ahead of Q2 results on YUTREPIA momentum

    The stock of Liquidia Technologies rose 2.7% in premarket trading after the company announced its Q2 2026 results before the open and a management webcast at 8:30 a.m. ET. Analyst consensus expects about $165 million in revenue and $0.70 EPS, supported by a history of positive earnings surprises. Strong commercialization of YUTREPIA (over 4,500 prescriptions, about 3,750 treatment starts, conversion rate ≥85%) and recent price-target increases (including H.C. Wainwright $130, BTIG $109) are driving positive sentiment; the stock has gained about 105% since the end of March. » Plus sur de.investing.com

Données financières

Au dernier trimestre, Liquidia a réalisé un chiffre d'affaires de 198,91 M € et un bénéfice net de -208,64 M €

(EUR) septembre 2026
YoY
Chiffre d'affaires 198,91 M 329,54 %
Bénéfice brut 185,86 M 326,26 %
Bénéfice net -208,64 M 6 830,31 %
EBITDA -232,17 M 7 107,58 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
4,47 Md €
Nombre d'actions
90,11 M
Plus haut/bas sur 52 semaines
85,31 € - 20,33 €
Dividendes Non
Bêta
0,54
Ratio P/E
-52,84
Ratio PEG
0,03
Ratio P/B
-191,58
Ratio P/S
7,89

Profil de l'entreprise

Liquidia Corporation, une entreprise biopharmaceutique, développe, fabrique et commercialise divers produits répondant à des besoins non satisfaits des patients aux États-Unis. Ses candidats médicaments comprennent YUTREPIA, une formulation de poudre sèche inhalable de tréprostinil destinée au traitement de l'hypertension artérielle pulmonaire. Elle distribue également une solution injectable générique de tréprostinil aux États-Unis. Liquidia Corporation a été fondée en 2004 et son siège social se situe à Morrisville, en Caroline du Nord.

Nom
Liquidia
PDG
Roger A. Jeffs
Siège social Morrisville, nc
États-Unis
Site web
Secteur
Matériaux
Industrie
Produits chimiques
Introduction en bourse
26/07/2018
Employés 216

Symboles boursiers

Bourse Symbole
NASDAQ
LQDA
Frankfurt
LT4.F
Düsseldorf
LT4.DU
München
LT4.MU
🍪

Parqet  utilise des cookies. En savoir plus